Piper Sandler analyst David Westenberg notes that Natera published its CIRCULATE study data in Nature, a top tier academic journal, on colorectal cancer MRD, which he thinks came in with good data, suggesting that Signatera is useful for determining whether to put patients on adjuvant chemotherapy. Westenberg would expect guideline inclusion in CRC to lead to meaningful impacts to ASPs, potentially to over $1,000. He also notes that about 30% of Signatera volume currently is related to CRC. Given this publication, Westenberg thinks NCCN guideline inclusion for Signatera in CRC is possible in late 2023. The analyst has an Overweight rating on the shares with a price target of $70.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NTRA:
- Natera announces publication of new study on ability of Signatera test
- Here’s why Natera is jumping in afternoon trading
- ACMG recommends 22Q screening, Natera runs micro deletion, says Piper Sandler
- ACMG publishes new guideline recommending NIPS for all pregnant individuals
- ACMG updated recommendations a positive for Natera, Myriad, says Stephens